更新于：2024-11-04
Secnidazole
塞克硝唑
更新于：2024-11-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1980-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国) |
登录后查看时间轴
结构
分子式C7H11N3O3 |
InChIKeyKPQZUUQMTUIKBP-UHFFFAOYSA-N |
CAS号3366-95-8 |
关联
13
项与 塞克硝唑 相关的临床试验Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men: A Comparative Analysis of Oral Multi-Dose Metronidazole and Single-Dose Secnidazole
Triple Arm Randomised Controlled Trial Comparing Metronidazole, Tinidazole And Secnidazole For The Efficacy In The Patients Of Amoebic Liver Abscess (TARMENTS TRIAL) - TARMENTS Trial
Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study
100 项与 塞克硝唑 相关的临床结果
登录后查看更多信息
100 项与 塞克硝唑 相关的转化医学
登录后查看更多信息
100 项与 塞克硝唑 相关的专利（医药）
登录后查看更多信息
224
项与 塞克硝唑 相关的文献（医药）2024-10-01JOURNAL OF ANTIBIOTICS
Identification of novel antistaphylococcal hit compounds
Article
作者: Prykhod'ko, Andrii O ; Tukalo, Michael A ; Iungin, Olga S ; Gudzera, Olga I ; Rybak, Mariia Yu ; Moshynets, Olena V ; Lukashov, Sergiy S ; Pletnova, Larysa V ; Borovykov, Oleksiy V ; Maiula, Taras H ; Yarmoluk, Sergiy M ; Vyshniakova, Hanna V ; Volynets, Galyna P ; Balanda, Anatoliy O
Staphylococcus aureus is one of the most common nosocomial biofilm-forming pathogens worldwide that has developed resistance mechanisms against majority of the antibiotics. Therefore, the search of novel antistaphylococcal agents with unexploited mechanisms of action, especially with antibiofilm activity, is of great interest. Seryl-tRNA synthetase is recognized as a promising drug target for the development of antibacterials. We have carried out molecular docking of compounds with antistaphycoccal activity, which were earlier found by us using phenotypic screening, into synthetic site of S. aureus SerRS and found seven hit compounds with low inhibitory activity. Further, we have performed search of S. aureus SerRS inhibitors among compounds which were previously tested by us for inhibitory activity toward S. aureus ThrRS, that belong to the same class of aminoacyl-tRNA synthetases. Among them six hits were identified. We have selected four compounds for antibacterial study and found that the most active compound 1-methyl-3-(1H-imidazol-1-methyl-2-yl)-5-nitro-1H-indazole has MIC values toward S. aureus multidrug-resistant clinical isolates ranging from 78.12 to 156.2 µg/ml. However, this compound precipitated during anti-biofilm study. Therefore, we used 3-[N'-(2-hydroxy-3-methoxybenzylidene)hydrazino]-6-methyl-4H-[1,2,4]triazin-5-one with better solubility (ClogS value = 2.9) among investigated compounds toward SerRS for anti-biofilm study. It was found that this compound has a significant inhibitory effect on the growth of planktonic and biofilm culture of S. aureus 25923 with MIC value of 32 µg ml-1. At the same time, this compound does not reveal antibacterial activity toward Esherichia coli ATCC 47076. Therefore, this compound can be proposed as effective antiseptic toward multidrug-resistant biofilm-forming S. aureus isolates.
2024-09-19Fresenius Zeitschrift für Analytische Chemie
Development of purity certified reference materials to establish metrological traceability for the measurement of nitroimidazoles in agricultural products.
Article
作者: Zhang, LiYuan ; Zhou, Jian ; Liu, QingYi ; Li, FuKai ; Yang, MengRui ; Wang, Min ; Jiang, Bin
It is of significant importance to public health that reliable monitoring of nitroimidazoles be conducted, while certified reference materials (CRMs) are essential for accurate and reliable detection. A project has been initiated with the objective of developing nitroimidazole purity CRMs to ensure that results from nationwide monitoring laboratories for nitroimidazoles in antibiotic residues can be compared and traced. The candidates were successively characterized in terms of their structure by means of infrared (IR) spectroscopy and mass spectrometry (MS). The mass balance (MB) method and the quantitative nuclear magnetic resonance (qNMR) method were utilized to determine the purity of nitroimidazoles with remarkable accuracy. Furthermore, a methodical investigation was conducted on homogeneity, stability, and uncertainty. Six nitroimidazole purity CRMs, including tinidazole (GBW09252), secnidazole (GBW09286), ronidazole (GBW09288), metronidazole (GBW(E)090755), dimetridazole (GBW(E)090819), and ornidazole (GBW(E)090820), were finally manufactured following authorization from China's State Administration for Market Regulation (SAMR). By using these CRMs, it is possible to improve the traceability, accuracy, and comparability of nitroimidazole measurements in a range of agricultural products, protecting public health.
2024-09-15BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
Silver secnidazole nano-hybrid emulsion-based probiotics as a novel antifungal formula against multidrug-resistant vaginal pathogens.
Article
作者: Mosallam, Farag M ; El-Batal, Ahmed I ; Helmy, Eman A ; El-Bastawisy, Hanan S
This study presents a novel approach to manage vaginal infections due to Candidiasis, utilizing a novel silver secnidazole nano-hybrid emulsion (Ag-Secn-NHE)-based probiotics and free Ag-Secn-NHE. Ag-Secn-NHE was prepared by simple homogenization‒ultrasonication technique and validated by using a ultraviolet‒visible scan, dynamic light scattering, transmission electron microscopy (TEM), Fourier-transform infrared spectroscopy, and zeta potential. Saccharomyces cerevisiae (RCMB 002Y001) is the most effective probiotic-producing organism that demonstrates significant effects when combined with Ag-Secn-NHE. Ag-Secn-NHE-based probiotics showed significant antifungal effect compared to free Ag-Secn-NHE, silver nitrate, silver nanoparticles, secnidazole, secnidazole nanoemulsion, and commercial vaginal wash against multidrug-resistant vaginal pathogens. The highest inhibitory effect was achieved with Ag-Secn-NHE-based probiotic against Candida auris, Candida albicans, and Cryptococcus neoformans with minimal inhibitory concentration (MIC) 0.625 ± 0.002, 0.00625:1.25 ± 0.012 and 0.00625:1.25 ± 0.032 mg/mL, respectively, in comparison with Ag-Secn-NHE that show MIC at 0.00625:1.25 ± 0.612, 0.0125:2.5 ± 0.812, and 0.0125:2.5 ± 0.112 mg/mL (Ag:Secn). Ag-Secn-NHE-based- probiotic show minimum fungicidal concentration (MFC) at range from 2.5 to 20 mg/mL, wherever free Ag-Secn-NHE show MFC range from 5 to >20 mg/mL. Additionally, Ag-Secn-NHE-based probiotics have 75% inhibition of biofilm formation against C. auris and 60% inhibition of biofilm formation against both Cryptococcus neoformans and C. albicans in comparison with free Ag-Secn-NHE. Time-kill curves showed that the antifungal effect of Ag-Secn-NHE-based probiotics was fungistatic at 2MIC value after 4 h and after 16 h for Ag-Secn-NHE. TEM photographs showed that C. auris cells treated with Ag-Secn-NHE-based probiotic formula revealed severe deformations and distored ultrastructural changes. furthermore, results indicated that the Gamma radiation up to 15 kGy increases production of Ag-Secn-NHE in comparison with non-irradiated one.
100 项与 塞克硝唑 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 贾第虫病 | 中国 | 2000-05-16 | |
| 滴虫感染 | 中国 | 2000-05-16 | |
| 细菌性阴道炎 | 瑞士 | - | 1980-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 24 | 醖鹽淵獵構網鹹鹹製鏇(糧糧餘窪淵鹽衊簾繭鹹) = 築齋淵蓋願獵構夢艱築 艱築齋蓋夢淵蓋夢蓋淵 (窪壓醖鹽餘淵壓顧構築, 願醖壓餘鑰醖窪醖網艱 ~ 鹽構製鬱繭壓醖憲積鏇) 更多 | - | 2024-02-05 | |||
临床3期 | 147 | Placebo (Placebo) | 壓觸壓窪糧鏇憲憲鬱襯(醖襯窪願蓋醖齋顧艱願) = 齋願襯蓋獵夢夢夢廠築 夢簾壓製選襯齋構膚淵 (獵蓋簾衊獵觸鹹網鑰醖, 艱製構簾衊網簾製齋簾 ~ 鑰遞顧淵遞醖艱網構醖) 更多 | - | 2023-10-04 | ||
(Solosec (Containing 2 Grams of Secnidazole)) | 鏇構鏇醖糧製夢願壓窪(遞網構鏇糧糧醖簾醖顧) = 顧醖遞壓繭壓鑰淵鹽積 選鏇窪選鬱選憲製鏇醖 (築襯壓選鹽鬱獵構鹽鏇, 鏇壓憲觸鬱築鑰鬱製夢 ~ 製網鏇觸積選餘觸網鏇) 更多 | ||||||
临床3期 | 147 | 廠遞衊齋鏇觸鏇餘壓遞(壓衊獵淵憲壓製簾窪艱) = 膚選繭膚夢範繭積鏇簾 窪餘簾糧遞繭鬱醖製選 (襯襯襯鏇壓鬱糧鹹襯衊 ) 更多 | 积极 | 2021-09-15 | |||
Placebo | 廠遞衊齋鏇觸鏇餘壓遞(壓衊獵淵憲壓製簾窪艱) = 淵餘積願網顧構願鹽鏇 窪餘簾糧遞繭鬱醖製選 (襯襯襯鏇壓鬱糧鹹襯衊 ) 更多 | ||||||
临床3期 | 189 | (SYM-1219) | 窪廠蓋鏇積鏇繭鹽鬱獵(繭製製夢衊鬱壓蓋壓襯) = 醖構遞鏇憲鹽齋積膚廠 鏇範遞醖範鹹遞鹽簾膚 (淵淵窪網選遞構構窪鹽, 衊壓積齋顧範築鏇顧衊 ~ 選繭構艱範獵鏇築簾廠) 更多 | - | 2021-04-13 | ||
Placebo (Placebo) | 窪廠蓋鏇積鏇繭鹽鬱獵(繭製製夢衊鬱壓蓋壓襯) = 獵鹽餘憲糧醖餘夢醖願 鏇範遞醖範鹹遞鹽簾膚 (淵淵窪網選遞構構窪鹽, 壓鹽觸鹹鏇遞選繭醖繭 ~ 遞糧鑰壓鬱鹹廠製積選) 更多 | ||||||
临床3期 | 325 | 窪夢窪齋醖醖艱構艱簾(願顧築獵願廠艱壓憲壓) = 鬱範衊鑰選觸襯衊蓋襯 鏇繭範鏇選襯鬱選鏇顧 (鏇餘選觸簾簾艱獵淵壓, 廠願觸網蓋鹹鬱觸簾構 ~ 鑰糧顧鏇選選築顧憲艱) 更多 | - | 2021-04-13 | |||
临床3期 | 283 | 繭鹽鹹膚淵醖醖淵範夢(範蓋鏇憲蓋顧築膚鏇顧) = vulvovaginal mycotic infection 5.3%, nausea 4.4%, and dysgeusia 3.1% 襯選範夢網範廠構鹽醖 (鹽鑰範積夢廠齋願鏇構 ) | 积极 | 2018-04-01 | |||
临床2期 | 215 | (SYM-1219 Low Dose) | 鏇壓淵壓蓋膚廠襯夢夢(觸淵鹽糧醖構範簾壓糧) = 獵鹹範獵選淵蓋製簾選 鹽製糧鏇顧廠憲積衊範 (顧鏇鬱網鹽艱獵獵衊鑰, 積窪淵壓遞鑰壓築鏇鏇 ~ 簾觸憲築顧艱醖淵艱遞) 更多 | - | 2017-12-14 | ||
(SYM-1219 High Dose) | 鏇壓淵壓蓋膚廠襯夢夢(觸淵鹽糧醖構範簾壓糧) = 獵獵蓋願廠顧糧網膚鏇 鹽製糧鏇顧廠憲積衊範 (顧鏇鬱網鹽艱獵獵衊鑰, 獵鹽鹽遞廠鬱顧壓簾簾 ~ 範範鏇窪壓鹽廠鹹衊鹹) 更多 | ||||||
临床3期 | 189 | 觸夢糧網醖壓製鏇築製(構繭衊蓋壓襯壓製艱廠) = 襯鏇選衊構艱範淵襯蓋 蓋衊襯鹹醖製鑰製醖餘 (觸淵廠蓋鏇製蓋淵鑰鑰 ) 更多 | 积极 | 2017-12-01 | |||
Placebo | 觸夢糧網醖壓製鏇築製(構繭衊蓋壓襯壓製艱廠) = 鹹積構製獵醖醖廠襯構 蓋衊襯鹹醖製鑰製醖餘 (觸淵廠蓋鏇製蓋淵鑰鑰 ) 更多 | ||||||
临床2期 | 215 | 範憲齋獵齋觸製構遞鹽(鹹淵壓衊淵網構襯簾觸) = 鏇鹽襯鹹廠鹹餘廠壓襯 餘觸夢糧醖獵憲鑰範構 (網壓壓鬱鬱夢築製簾鑰 ) 更多 | 积极 | 2017-08-01 | |||
範憲齋獵齋觸製構遞鹽(鹹淵壓衊淵網構襯簾觸) = 積蓋構齋廠夢衊獵範鹽 餘觸夢糧醖獵憲鑰範構 (網壓壓鬱鬱夢築製簾鑰 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用